258 related articles for article (PubMed ID: 35592841)
41. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
42. The Cost-Effectiveness of Congenital Adrenal Hyperplasia Newborn Screening in Brazil: A Comparison Between Screened and Unscreened Cohorts.
de Miranda MC; Haddad LBP; Trindade E; Cassenote A; Hayashi GY; Damiani D; Costa FC; Madureira G; de Mendonca BB; Bachega TASS
Front Pediatr; 2021; 9():659492. PubMed ID: 34109139
[No Abstract] [Full Text] [Related]
43. [A cost-benefit evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism].
Gu X; Wang J; Ye J; Cheng X
Zhonghua Yu Fang Yi Xue Za Zhi; 2000 May; 34(3):147-9. PubMed ID: 11860921
[TBL] [Abstract][Full Text] [Related]
44. Newborn hearing screening: the great omission.
Mehl AL; Thomson V
Pediatrics; 1998 Jan; 101(1):E4. PubMed ID: 9417168
[TBL] [Abstract][Full Text] [Related]
45. Estimating epidemiological and economic burden and community derived disability weights for snake bite in Kerala: a study protocol.
Menon JC; John D; Menon GR; Joseph JK; Suseela PR; Pillay VV; Banerjee A
F1000Res; 2021; 10():167. PubMed ID: 34316357
[No Abstract] [Full Text] [Related]
46. Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism.
Geelhoed EA; Lewis B; Hounsome D; O'leary P
J Paediatr Child Health; 2005 Nov; 41(11):575-9. PubMed ID: 16398841
[TBL] [Abstract][Full Text] [Related]
47. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
48. Economic benefit of carpal tunnel release in the Medicare patient population.
Hubbard ZS; Law TY; Rosas S; Jernigan SC; Chim H
Neurosurg Focus; 2018 May; 44(5):E16. PubMed ID: 29712517
[TBL] [Abstract][Full Text] [Related]
49. Burden of chikungunya in India: estimates of disability adjusted life years (DALY) lost in 2006 epidemic.
Krishnamoorthy K; Harichandrakumar KT; Krishna Kumari A; Das LK
J Vector Borne Dis; 2009 Mar; 46(1):26-35. PubMed ID: 19326705
[TBL] [Abstract][Full Text] [Related]
50. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
[TBL] [Abstract][Full Text] [Related]
51. Antenatal syphilis screening using point-of-care testing in low- and middle-income countries in Asia and Latin America: a cost-effectiveness analysis.
Kuznik A; Muhumuza C; Komakech H; Marques EM; Lamorde M
PLoS One; 2015; 10(5):e0127379. PubMed ID: 26010366
[TBL] [Abstract][Full Text] [Related]
52. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
53. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
[TBL] [Abstract][Full Text] [Related]
55. Economic costs of childhood stunting to the private sector in low- and middle-income countries.
Akseer N; Tasic H; Nnachebe Onah M; Wigle J; Rajakumar R; Sanchez-Hernandez D; Akuoku J; Black RE; Horta BL; Nwuneli N; Shine R; Wazny K; Japra N; Shekar M; Hoddinott J
EClinicalMedicine; 2022 Mar; 45():101320. PubMed ID: 35308896
[TBL] [Abstract][Full Text] [Related]
56. Congenital hypothyroidism control programs. A cost-benefit analysis.
Layde PM; Von Allmen SD; Oakley GP
JAMA; 1979 May; 241(21):2290-2. PubMed ID: 108409
[TBL] [Abstract][Full Text] [Related]
57. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
58. The economics of screening infants at risk of hearing impairment: an international analysis.
Burke MJ; Shenton RC; Taylor MJ
Int J Pediatr Otorhinolaryngol; 2012 Feb; 76(2):212-8. PubMed ID: 22129917
[TBL] [Abstract][Full Text] [Related]
59. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
60. Global, regional, and country-level cost of leptospirosis due to loss of productivity in humans.
Agampodi S; Gunarathna S; Lee JS; Excler JL
PLoS Negl Trop Dis; 2023 Aug; 17(8):e0011291. PubMed ID: 37616329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
